Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. JULUCA (dolutégravir sodique/ rilpivirine (chlorhydrate de))
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

JULUCA (dolutégravir sodique/ rilpivirine (chlorhydrate de))

Medicine - Posted on Sep 18 2025
Active substance (DCI)
  • dolutégravir
  • rilpivirine
history (3)
  • 8/27/25

    JULUCA (dolutégravir/rilpivirine) - VIH

    Modification des conditions de l'inscription L'essentiel Avis favorable au maintien du remboursement dans le traitement de d...
    CAV :
    54321
    icône flèche
  • 9/22/21

    JULUCA 50 mg/25 mg (rilpivirine / dolutégravir)

    Modifications de l’AMM. Avis favorable au maintien du remboursement dans le traitement de l'infection par le virus de l’immu...
    icône flèche
  • 7/25/18

    JULUCA (dolutegravir/rilpivirine), combination of anti-viral agents

    High clinical benefit in the treatment of HIV infection in adults who are virologically-suppressed, but no demonstrated clin...
    CAV :
    54321
    icône flèche
Technical information
ATC code
  • J05AR21
Manufacturer
ViiV HEALTHCARE SAS
Presentation

JULUCA 50 mg/25 mg, comprimé pelliculé (code CIS : 63504750)
1 flacon polyéthylène haute densité (PEHD) avec fermeture de sécurité enfant de 30 comprimés (CIP : 34009 301 448 2 4)

All our publications
    Drug therapy Immunologic deficiency syndromes Sexually transmitted diseases Virus diseases

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
5k286AMYNLrNbmm6